The search for novel antiarrhythmic strategies

Japanese Circulation Journal

Volumn 62, Issue 9, 1998, Pages 633-648

  Rosen, Michael R ^a   Pfeiffer, Gustavus A ^a   Camm, A John ^b  

^a Department of Pharmacology ^*  (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Arrhythmogenic substrates; Clinical trials; Targeted antiarrhythmic therapy; Triggering factors for arrhythmias

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE FUMARATE; LIDOCAINE; METOPROLOL; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; WARFARIN;

CLINICAL TRIAL; DEFIBRILLATOR; DRUG MECHANISM; EARLY DIAGNOSIS; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE FIBRILLATION; HUMAN; HUMAN TISSUE; LONG QT SYNDROME; META ANALYSIS; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; SUDDEN DEATH;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ATRIAL FIBRILLATION; CHROMOSOME MAPPING; DOGS; DRUG DESIGN; ELECTRIC COUNTERSHOCK; GOATS; HUMANS; LONG QT SYNDROME; MODELS, BIOLOGICAL; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 0031665051     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.62.633     Document Type: Review

References (160)

1. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology: The Sicilian Gambit. A New Approach to the Classification of Antiarrhythmic Drugs Based on Their Actions on Arrhythmogenic Mechanisms. Circulation 1991;84: 1831-1851
2. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology: The Sicilian Gambit. A New Approach to the Classification of Antiarrhythmic Drugs Based on Their Actions on Arrhythmogenic Mechanisms. Eur Heart J 1991; 12: 1112-1131
3. Members of the Sicilian Gambit. Antiarrhythmic Therapy: A Pathophysiologic Approach. Futura Publishing Company, Armonk, NY; 1994
4. Waldo AL, Camm AJ, Deruyter H, Friedman PL, Macneil DJ, Pauls JF, et al: Effect of d-sotalol on mortality in patients with left ventric-ular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12
5. Cairns JA, Connolly SJ, Roberts R, Gent M: the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997; 349: 675-682
6. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al: the European Myocardial Infarct Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997; 349: 667-674
7. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al: Amiodarone in patients with congestive heart failure and asymptomatic centricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77-82
8. Scherf D, Schott A: Extrasystoles And Allied Arrhythmias. Yearbook Medical Publishers, Chicago, IL, 1973
9. Mautz FR: Reduction of cardiac irritability by epicardial and systemic administration of drugs as protection in cardiac surgery. J Thorac Surg 1936; 5:612
10. Frey W: Über Vorhofflimern beim Menschen und seine Beseitigung durch Chiniden. Berl klin Wschr 1918; 55: 417-450
11. Mark LC, Kayden JJ, Steele JM, Cooper JR, Berlin I, Rovestine EA, et al: The physiological disposition and cardiac effects of procaineamide. J Pharmacol Exp Ther 1951; 102: 5-15
12. Hondeghem LM: Class III agents: amiodarone, bretylium, and sotalol. In: Zipes D, Jalife J, editors. Cardiac Electrophysiology: From Cell To Bedside. Philadelphia: Saunders, 1995: 1330-1335
13. McFarlane P, Lawrie, TDV: Comprehensive Electrocardiology: Theory and Practice in Health and Disease Vol 3. Pergamon Press, Oxford, England, 1989
14. Rosenbaum MB, Blanco HH, Elizari MV, Lazzari JQ, Davidenko J: Electrotonic modulation of the T wave and cardiac memory. Am J Cardiol 1982; 50: 213-222
15. Chatterjee K, Harris A, Davies G, Leatham A: Electrocardiographic changes subsequent to artificial ventricular depolarization. Br Heart J 1969; 31: 770-779
16. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968
17. Ziegler RF: Patent ductus artcriosus. In: Moss AJ, Adams FH, editors. Heart Disease in Infants, Children and Adolescents. Baltimore: Williams and Wilkins, 1968: 338-357
18. Boyden PA, Jeck CD: Ion channel function in disease. Cardiovasc Res 1995; 29: 312-318
19. Hondeghem L: Ideal antiarrhythmic agents: chemical defibrillators. J Cardiovasc Electrophysiol 1991; 2: S169 - S177
20. Gintant GA: Two components of delayed rectifier current in canine atrium and ventricle. Circ Res 1996; 78: 26-37
21. Liu D-W, Antzelevitch C: Characteristics of the delayed rectifier current (IKr and IKs) in a canine epicardial, midmyocardial and endocardial myocytes. Circ Res 1995; 76: 351-365
22. Splawski I, Tristani-Firouzi M, Lehmann M, Sanguinetti M, Keating M: Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nature Genetics 1997; 17: 338-340
23. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-780
24. Sanguinetti MC, Jiang C, Curran ME, Keating MT: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81: 299-307
25. + channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci 1996a; 93: 2208-2212
26. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, et al: Coassembly of KvLQT1 and minK (IsK) proteins to form cardiac IKs potassium channel. Nature 1996; 384: 80-83
27. Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, et al: Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Molec Gen 1995; 4: 1603-1607
28. Wang Q, Shen J, Splawski I, Atkinson D, Li Z: SCN5A mutations associated with an Inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80: 805-811
29. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, Vanraay TJ, et al: Positional cloning of a novel potassium channel gene: KVLQTI mutations cause cardiac arrhythmias. Nature Genetics 1996; 12: 17-23
30. Schott JJ, Charpentier F, Peltier S, Foley P, Drouin E, Bouhour JB, et al: Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet 1995; 57: 1114-1122
31. Roden DM, Lazzara R, Rosen M, Schwanz P, Towbin J, Vincent GM: Multiple mechanisms in the long-QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996; 94: 1996-2012
32. Schwartz PJ: The Long QT Syndrome-Clinical Approaches to Tachyarrhythmias series - Camm AJ, editor. Armonk: Futura, 1997: 1-108
33. + channel mutations in Romano-Ward and Jervell and Lange-Nielsen inherited cardiac arrhythmias. EMBO 1997; 16: 5472-5479
34. Shalaby FY, Levesque PC, Yang W-P, Little WA, Conder ML, Jenkins-West T, et al: Dominant-negative KvLQT1 mutations underlie the LQT1 form of long QT syndrome. Circulation 1997; 96: 1733-1736
35. Bennett PB, Yazawa K, Makita N, George AL Jr: Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995; 376: 683-685
36. Dumaine R, Wang Q, Keating MT, Hartmann HA, Schwartz PJ, Brown AM, et al: Multiple mechanisms of sodium channel-linked long QT syndrome. Circ Res 1996; 78: 916-924
37. + in canine and guinea pig Purkinje fibers. J Cardiovasc Electrophysiol 1995; 6: 796-812
38. 2+ current. Circ Res 1989; 64: 977-990
39. Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R: Bradycardia-dependent triggered activity: Relevance to drug induced multiform ventricular tachycardia. Circulation 1983; 68: 846-856
40. + channel blockade and to increases in heart rate: Implications for gene-specific therapy. Circulation 1995; 92: 3381-3386
41. + channels. Circ Res 1996; 79: 103-108
42. Schwartz PJ, Priori SG, Locati EH, Napolitano C, Stramba-Badiale M, Diehl L, et al: QTc responses to mexiletine and to heart rate changes differentiate LQT1 from LQT3 but not from LQT2 patients. Circulation 1996; 94: 1-204
43. + currents. Pflügers Arch 1992; 420: 180-186
44. + current in cardiac cells. Circ Res 1997; 80: 782-789
45. Compton SJ, Lux RL, Ramsey MR, Strelich KR, Sanguinetti MC, Green LS, et al: Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996; 94: 1018-1022
46. McAllister RE, Noble D: The time and voltage dependence of the slow outward current in cardiac Purkinje fibres. J Physiology 1996; 186: 632-662
47. Choy AM, Lang CC, Chomsky DM, Rayos GH, Wilson JR, Roden DM: Normalization of acquired QT prolongation in humans by IV potassium. Circulation 1997; 96: 2149-2154
48. Wang DW, Yazawa K, Makita N, George AL Jr, Bennett PB: Pharmacological targeting of long QT mutant sodium channels. J Clin Invest 1997; 99: 1714-1720
49. Schwartz PJ: Idiopathic long QT syndrome: Progress and Questions. Am Heart J 1985; 109: 399-411
50. Schwartz PJ, Priori SG: Sympathetic nervous system and cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology. From Cell to Bedside. Philadelphia: Saunders, 1990: 330-343
51. Bliddal J: Familial atrial fibrillation and otosclerosis. In: Sandøe E, Flensted-Jensen E, Olesen K, editors. Symposium On Cardiac Arrhythmias. Sweden: AB Astra, 1970; 109-125
52. Brugada R, Tapscott T, Czernuszewicz GZ, Marian AJ, Iglesias A, Mont L, et al: Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997; 336: 905-911
53. Falk RH: Control of the ventricular rate in atrial fibrillation. In: Falk RH, Podrid PJ, editors. Atrial Fibrillation: Mechanisms and Management. NY: Raven, 1992: 255-282
54. Nattel S, Wang Z, Pelletier LC, Carrier M, Meere C, Cartier R: Termination of atrial fibrillation by drugs. In: Allessie MA, Fromer M, editors. Atrial and Ventricular Fibrillation: Mechanisms and Device Therapy. Armonk: Futura. 1997: 199-214
55. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI: Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41-46
56. Allessie MA, Lammers WJEP, Bonke FIM, Hollen J: Experimental evaluation of Moe's multiple wavelet of atrial fibrillation, In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology and Arrhythmias. Orlando: Grune & Stratton, 1985: 265-276
57. Schuessler RB, Grayson TM, Bromberg BI, Cox JL, Boineau JP: Cholinergically mediated tachyarrhythmias induced by a single extrastimulus in the isolated canine right atrium. Cire Res 1992; 71: 1254-1276
58. Waldo AL, Cooper TB: Spontaneous onset of type I atrial flutter in patients. J Am Coll Cardiol 1996; 28: 707-712
59. Jais P, Haissaguerre M, Shah DC, Chouairi S, Gencel L, Hocini M, et al: A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997; 95: 572-576
60. Cox JL, Canavan TE, Schuessler RB, Cain ME, Lindsay BD, Stone C: The surgical treatment of atrial fibrillation. II: Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac Cardiovasc Surg 1991; 101: 406-426
61. Cox JL, Schuessler RB, D'Agostino HJ, Stone CM, Chang BC, Cain ME, et al: The surgical treatment of atrial fibrillation. III: Development of a definitive surgical procedure. J Thorac Cardiovasc Surg 1991b; 101: 569-583
62. Kouings KTS, Kirchof CJHJ, Smeets JRLM, Wellens HJJ, Penn OC, Allessie MA: High-density mapping of electrically induced atrial fibrillation in humans. Circulation 1994; 89: 1665-1680
63. Kumagai K, Khrestian C, Waldo AL: Simultaneous multisite mapping during induced atrial fibrillation in the sterile pericarditis model: Insights into the mechanism of its maintenance. Circulation 1997; 95: 511-521
64. Haissaguerre M, Gencel L, Fisher B Le Métayer P, Poquet F, Marcus FI, et al: Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 1994; 5: 1045-1052
65. Swartz JF, Pellerseis G, Silvers J, Patten L, Cervantez D: A catheter-based curative approach to atrial fibrillation in humans. Circulation 1994; 90: I-355
66. Elvan A, Pride HP, Eble JN, Zipes DP: Radiofrequency catheter ablation of the atria reduces the inducibilty and duration of atrial fibrillation in dogs. Circulation 1995; 91: 2235-2244
67. Haissaguerre M, Jais P, Shah DC, Gencel L, Pradeau V, Garriques S, et al: Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996; 7: 1132-1144
68. Attuel P, Childers R, Cauchemex B, Poveda J, Mugica J, Coumel P: Failure in the rate adaptation of the atrial refractory period: its relationship to vulnerability. Int J Cardiol 1982; 2: 179-197
69. Boutjdir M, Le Heuzey JY, Lavergne T, Chauvaud IS, Guize L, Carpentier L, et al: Inhomogeneity of cellular refractoriness in human atrium: factor of arrhythmia? PACE 1986; 9: 1095-1100
70. Ramdat Misier AR, Opthof T, van Hemel NM, Defauw JJAM, de Bakker JMT, Janse MJ, et al: Increased dispersion of "refractoriness" in patients with idiopathic paroxysmal atrial fibrillation. J Am Coll Cardiol 1992; 19: 1531-1535
71. Daoud EG, Begun F, Goyal R, Harvey M, Man KC, Strickberger SA, et al: Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996; 94: 1600-1606
72. Le Grand B, Hatem SD, Deroubaix E, Couétil JP, Coraboeuf E: Depressed transient outward and calcium currents in dilated human atria. Cardiovasc Res 1994; 28: 548-556
73. Wijffels MCEF. Atrial fibrillation begets atrial fibrillation. Thesis; University of Maastricht, 1996. Universitaire Pers, Maastricht.
74. Goette A, Honeycutt C, Langberg JJ: Electrical remodeling in atrial fibrillation. Circulation 1996; 94: 2968-2974
75. + Current Densities and Kv1.5 Expression Are Reduced in Chronic Human Atrial Fibrillation. Circ Res 1997; 80: 772-781
76. Mary-Rabine L, Albert A, Pham TD, Hordof A, Fenoglio JJ Jr, Malm JR, et al: The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure. Circ Res 1983; 52: 188-199
77. Coumel P: Neural aspects of paroxysmal atrial fibrillation. In: Falk RH, Podrid PJ, editors. Atrial Fibrillation: Mechanisms and Management. New York: Ravens, 1992: 109-125
78. The Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [published erratum appears in Arch Intern Med 1994; 154: 1449-1457
79. Daubert C, Mabo P, Berder V, Gras D, Leclercq C: Atrial tachyarrhythmias associated with high degree interatrial conduction block: prevention by permanent atrial resynchronization. Eur J Cardiac Pacing and Electrophysiol 1994; 4: 35-44
80. Saksena S, Prakash A, Hill M, Krol RB, Munsif AN, Mathew PP, et al: Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing. J Am Coll Cardiol 1996; 28: 687-694
81. Levy S, Morady F: A randomized comparison of external and internal cardioversion of chronic atrial fibrillation [letter]. Circulation 1993; 87: 1052
82. Cox JL, Boineau JP, Schuessler RB, Kater KM, Ferguson TB, Jr, Cain ME, et al: Electrophysiologic basis, surgical development, and clinical results of the maze procedure for atrial flutter and atrial fibrillation. Adv Card Surg 1995; 6: 1-67
83. Scherf D: Studies on auricular tachycardia caused by aconitine administration. Proc Soc Exp Biol Med 1947; 64: 233-239
84. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82: 1106-1116
85. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992; 20: 527-532
86. Deedwania PC, Singh BN, Fletcher R, Fisher S, Singh S: Amiodarone improves survival by restoring and maintaining sinus rhythm in patients with chronic atrial fibrillation, dilated cardiomyopathy, and congestive heart failure. Circulation 1996; 94: I-667
87. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, et al: Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989; 80: 1557-1570
88. Echt DS, Liehson PR, Mitchell LB, Peters RW, Obias Manno D, Barker AH, et al: Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781-788
89. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC, Meissner MD: Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response study. J Am Coll Cardiol 1996; 28: 130-136
90. Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani B: Propafenone for conversion of recent-onset atrial fibrillation. Chest 1995; 108: 355-358
91. Gallagher MM, Camm AJ: Classification of atrial fibrillation. PACE 1997; 20: 1603-1605
92. de Bakker JMT, van Capelle FJL, Janse MJ, Tasseron S, Vermeulen JT, Dejonge N, et al: Slow conduction in the infarcted human heart -zigzag course of activation. Circulation 1993; 88: 915-926
93. Myerburg RJ, Kessler KM, Bassett AL, Castellanos A: A biological approach to sudden cardiac death: Structure, function and cause. AM J Cardiol 1989; 63: 1512-1516
94. Myerburg RJ, Kessler KM, Castellanos A: Sudden cardiac death: Structure, function and time-dependence of risk. Circulation 1992; 85: I-2-I-10
95. Myerburg RJ, Kessler KM, Castellanos A: Sudden cardiac death: Epidemiology, transient risk and intervention assessment. Ann Int Med 1993; 119: 1187-1197
96. Zipes D, Mitrani R, Klein L, Miles W: Cardiac sympathetic scintigraphy. In: Cardiac Electrophysiology: From Cell To Bedside. Zipes D, Jalife J, editors. Philadelphia: Saunders. 1995: 1129-1133
97. Vermeulen JT, Tan HL, Rademaker CA, Schumacher CA, Loh P, Opthof T: Electrophysiologic and extracellular ionic changes during acute ischemia in failing and normal rabbit myocardium. J Mol Cell Cardiol 1996; 28: 123-131
98. Schwartz PJ, Billman GE, Stone HL: Autonomie mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with a healed myocardial infarction. An experimental preparation for sudden cardiac death. Circulation 1984; 64: 790-800
99. Kleiger RE, Miller JP, Bigger JT, Moss AJ: Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-262
100. Huikuri HV, Linnaluoto MK, Seppanen T, Airaksinen KE, Kessler KM, Takkunen JT, et al: Circadian rhythm of heart rate variability in survivors of cardiac arrest. Am J Cardiol 1992; 70: 610-615
101. Bigger JT Jr, Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN: Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992; 85: 164-171
102. Kozlovskis PL, Smets MJ, Duncan RC, Bailey BK, Bassett AL, Myerburg RJ: Regional β-adrenergic receptors and adenylate cyclase activity after healing of myocardial infarction in cats. J Mol Cell Cardiol 1990; 22: 311-322
103. Aggarwal R, Boyden PA: Diminished calcium and barium currents in myocytesurviving in the epicardial border zone of the 5 day infarcted canine heart. Circ Res 1995; 77: 1180-1191
104. 2+ currents in myocytes that survive in the infarcted heart. J Cardiovasc Electrophysiol 1996; 7: 20-35
105. Steinberg SF, Zhang HL, Pak E, Pagnotta G, Boyden PA: Characteristics of the adrenergic receptor complex in the epicardial border zone of the 5 day infarcted heart. Circulation 1995; 91: 2824-2833
106. de Bakker JMT, van Capelle FJL, Janse MJ, Wilde AAM, Coronel R, Becker AE: Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 1988; 77: 589-606
107. de Bakker JMT, Van Capelle FJL, Janse MJ, Vanhemel NM, Hauer RNW, Defauw JJAM: Macroreentry in the infarcted human heart -the mechanism of ventricular tachycardias with a focal activation pattern. J Am Coll Cardiol 1991; 18: 1005-1014
108. Dillon SM, Allessie MA, Ursell PC, Wit AL: Influences of anisotropic tissue structure on reentrant circuits in the epicardial border zone of subacute canine infarets. Circ Res 1988; 63: 182-206
109. Spear JF, Michelson EL, Moore EN: Reduced space constant in slowly conducting regions of chronically infarcted myocardium. Circ Res 1983; 53: 176-185
110. Matsubara H, Suzuki J, Inada M: Shaker-related potassium channel, Kv1.4, mRNA regulation in cultured rat heart myocytes and different expression of Kv1.4 and Kv1.5 genes in myocardial development and hypertrophy. J Clin Invest 1993; 92: 1659-1666
111. Mori Y, Matsubara H, Folco E, Siegel A, Koren G: The transcription of a mammalian voltage-gated potassium channel is regulated by cAMP in a cell-specific manner. J Biol Chem 1993; 268: 26482-26493
112. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ: Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991; 69: 475-482
113. Kaye D, Smith TW, Kelly RA: Role of transiently altered sarcolemmal membrane permeability and basic fibroblast growth factor release in the hypertrophic response of adult rat ventricular myocytes to increased mechanical activity in vitro. J Clin Invest 1996; 97: 281-291
114. Sadoshima J, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the ATI receptor subtype. Circ Res 1993; 73: 413-423
115. max and the transient outward current. Circulation 1992; 85: 1175-1188
116. Pu J, Boyden PA: Reduced sodium current density and function in myocytes from the epicardial border zone of the infarcted heart: A possible ionic mechanisms for altered excitability and post repolarization refractoriness. Circ Res 1997; 81: 1024-1033
117. Boyden PA, Pinto JM: Reduced calcium currents in subendocardial Purkinje myocytes that survive in the 24- and 48-hour infarcted heart. Circulation 1994; 89: 2747-2759
118. Jeck CD, Pinto JM, Boyden PA: Transient outward currents in subendocardial Purkinje myocytes surviving in the infarcted heart. Circulation 1995; 92: 465-473
119. Yuan F, Pinto JMB, Hong Z, Myerburg RJ, Bassett AL: Abnormal delayed rectifier potassium currents (IK) in feline left ventricular myocytes adjacent to healed myocardial infarct area. Circulation 1995; 92: 1-158
120. Pinto JMB, Yuan, F. Wasserlauf B, Bassett A, Myerburg R: Regional gradation of L-type calcium currents in the feline heart with a healed myocardial infarct. J Cardiovasc Electrophysiol 1997; 8: 548-560
121. Dolber PC, Beyer EC, Junker EL, Spach MS: Distribution of gap junctions in dog and rat ventricle studied with a double-label technique. J Moll Cell Cardiol 1992; 24: 1443-1457
122. Saffitz JE, Kanter HL, Green GK, Tolley TK, Beyer EC: Tissue specific determinants of anisotropic conduction velocity in canine atrial and ventricular myocardium. Circ Res 1994; 74: 1065-1070
123. Smith JH, Green CR, Peter NS, Rothery S, Severs NJ: Altered patterns of gap junction distribution in ischemic heart disease - an immunohistochemical study of human myocardium using laser scanning confocal microscopy. Am J Pathol 1991; 139: 801-821
124. Peters N, Coromilas J, Severs N, Wit A: Disturbed connexin 43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation 1997; 95: 988-996
125. Fast VG, Darrow BJ, Saffitz JE, Kléber AG: Anisotropic activation spread in heart cell monolayers assessed by high-resolution and optical mapping: role of tissue discontinuities. Circ Res 1996; 79: 115-127
126. Baker KM, Booz GW, Dostal DE: Cardiac actions of angiotensin II. Annu Rev Physiol 1992; 54: 227-241
127. Kent RL, McDermott PJ: Passive load and angiotensin II evoke differential responses of gene expression and protein synthesis in cardiac myocytes. Circ Res 1996; 78: 829-838
128. La Rovcre MT, Specchia G, Mortara A, Schwartz PJ: Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction: a prospective study. Circulation 1988; 78: 816-824
129. Furukawa T, Rozanski JJ, Nogami A, Moroe K, Gosselin AJ, Lister JW: Time-dependent risk of and predictors for cardiac arrest recurrence in survivors of out-of-hospital cardiac arrest with chronic coronary artery disease. Circulation 1989; 80: 599-608
130. The BHAT research group: A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707-1714
131. Hjalmarson A, Herlitz J, Malek I, Ryden L, Vedin A, Waldenstrom A, et al: Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981; 2: 823-827
132. Rutherford JD, Pfeffer MA, Moye LA, Davis BR, Flaker GC, Kowey PR, et al: Effect of captopril on ischemic events after myocardial infarction. Circulation 1994; 90: 1731-1738
133. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al: for the TRACE Investigators. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676
134. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of losartan in the Elderly Study). Lancet 1997; 349: 747-752
135. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
136. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al: Prevention of coronary heart disease with provastatin in men with hypercholesterolemia. New Engl J Med 1995; 333: 1301-1307
137. The Cardiac Arrhythmia Suppression Trial II Investigators: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-233
138. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J: Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled pilot study. J Am Coll Cardiol 1992; 20: 1056-1062
139. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D: Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990; 16: 1711-1718
140. Pfisterer M, Kiowski W, Burckhardt D, Follath F, Burkart F: Beneficial effect of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 1992; 69: 1399-1402
141. Garguichevich JJ, Ramos JL, Gambarte A, Gentile A, Hauad S, Scapin O: Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). Am Heart J 1995; 130: 494-500
142. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevide en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493-498
143. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC: Amiodarone in patients with congestive heart failure and asymptomatic centricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77-82
144. Amiodarone Trials Meta-Analysis Investigators: Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997; 350: 1417-1424
145. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al: Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation in Trial Investigators. New Engl J Med 1996; 335: 1933-1960
146. Spotnitz HM, Herre JM, Baker LD, Fitzgerald DM, Kron IL, Bigger Jr JT: for the Surgical Investigators, The CABG Patch Trial Circulation 1996; 94: 248-253
147. Bardy GH, Lee KL, Mark DB, Poole JE, Fishbein DP, Troutman C, et al: Sudden cardiac death in heart failure trial: pilot study. PACE 1997; 20: 1148
148. The CASCADE Investigators: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am J Cardiol 1993; 72: 280-287
149. Kleiger RE, Miller JP, Bigger JT, Moss AJ: the Multicenter Post-infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-262
150. Task Force of the European Society of Cardiology and the North American Society. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996; 93: 1043-1065
151. La Rovere MT, Mortara A, Bigger JT Jr, Marcus FL, Camm AJ, Hohnloser SH, et al: for the ATRAMI Investigators. The prognostic value of baroreflex sensitivity and heart rate variability after myocardial infarction: the ATRAMI study. Circulation 1996; 94: 1-19
152. Mason JW: A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardio-graphic Monitoring Investigators. N Engl J Med 1993; 329: 498-499
153. Mason JW: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring (ESVEM) Investigators. N Engl J Med 1993; 329: 452-458
154. Newman D, Sauve MJ, Herre J, Langberg JJ, Lee MA, Titus C, et al: Survival after implantation of the cardioverter defibrillator. Am J Cardiol 1992; 69: 899-903
155. Bocker D, Haverkamp W, Block M, Hammell D, Borggrefe M. Breithardt G: Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation 1996; 94: 151-157
156. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. New Engl J Med 1997; 337: 1576-1583
157. Connolly SJ, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ, et al: Canadian implantable defibrillator study (CIDS): Study design and organization. Am J Cardiol 1993; 72: 103F-108F
158. Siebels J, Kuck KH: Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994; 127: 1139-1144
159. Nisam S, Breithardt G: Mortality trials with implantable defibrillators. Am J Cardiol 1997; 79: 468-471
160. Bocker D, Haverkamp W, Block M, Hammel D, Borggrefe M, Breithardt G: Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation 1996; 94: 151-157